The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The two GLP-1 treatments available are sold under the brand names Byetta and Victoza. The drugs, however, are not very popular with consumers, and are not nearly as popular as they deserve to be, according to Edelman. “It’s a case of clinical inertia on behalf of doctors,” Edelman says regarding one reason why more GLP-1 prescriptions aren’t being written. Read more

My Wake Up Call: Bydureon and Possible Cancer Risk?

Last week, I attended  the Second Annual Diabetes Symposium at the Thomas Jefferson University. Surrounded by endocrinologists, nutritionists and diabetes educators, I sat through the lively presentations on new advances and innovations in diabetes. The news was not entirely encouraging … Read more

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments… Read more

Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe

The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes’ type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients… Read more

Bydureon Receives Positive Opinion From The European Medicines Agency

Eli Lilly and Company, Amylin Pharmaceuticals and Alkermes announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Bydureon for injection in the European Union for the treatment of type 2 diabetes in combination with… Read more

Positive Results for Once Monthly Type 2 Diabetes Drug

Positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes were announced by Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. Exenatide once monthly is a new… Read more

FDA Requests Further Testing On Amylin’s New Type 2 Diabetes Drug

In the complete response letter regarding the New Drug Application (NDA) for Bydureon (exenatide extended-release for injectable suspension) issued Tuesday the FDA requested Amylin Pharmaceuticals, Eli Lilly and Alkermesa conduct a thorough QT study which would look at the new drug’s effect on patients’ heart rates… Read more

New Type 2 Diabetes Drug Bydureon Shows Better Results Than Januvia

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of Bydureon (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications… Read more

Subscribe to our Newsletter

Hide me